Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date (Ascending) Package Discontinuation Date Status
23155-0779-71 23155-0779 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 June 15, 2022 No Longer Used
00409-1060-01 00409-1060 Pemetrexed Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 20, 2022 In Use
00409-1061-01 00409-1061 Pemetrexed Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 20, 2022 In Use
71335-2120-01 71335-2120 Pilocarpine hydrchloride Pilocarpine hydrchloride 5.0 mg/1 Ancillary Therapy Miscellaneous Agent Cholinergic Agonist Oral June 20, 2022 In Use
00409-1062-01 00409-1062 Pemetrexed Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 20, 2022 In Use
51655-0416-54 51655-0416 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral June 21, 2022 In Use
67184-0532-01 67184-0532 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral June 21, 2022 In Use
67184-0532-02 67184-0532 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral June 21, 2022 In Use
67184-0532-03 67184-0532 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral June 21, 2022 In Use
67184-0533-01 67184-0533 Imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral June 21, 2022 In Use
67184-0533-02 67184-0533 Imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral June 21, 2022 In Use
67184-0533-03 67184-0533 Imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral June 21, 2022 In Use
51655-0208-18 51655-0208 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral June 21, 2022 In Use
59651-0530-03 59651-0530 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0530-10 59651-0530 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0531-03 59651-0531 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0531-10 59651-0531 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0532-03 59651-0532 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0532-10 59651-0532 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
68001-0538-41 68001-0538 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 24, 2022 In Use
68001-0539-41 68001-0539 Pemetrexed disodium Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 24, 2022 In Use
70710-1839-01 70710-1839 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous June 24, 2022 In Use
70710-1839-08 70710-1839 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous June 24, 2022 In Use
58468-7860-03 58468-7860 Vandetanib CAPRELSA 300.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Oral June 24, 2022 In Use
50742-0492-01 50742-0492 Carmustine CARMUSTINE Chemotherapy Alkylating Agent Nitrosourea June 25, 2022 In Use

Found 10,000 results in 9 millisecondsExport these results